NO304576B1 - FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom - Google Patents

FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom Download PDF

Info

Publication number: NO304576B1
Authority: NO; Norway
Prior art keywords: compounds; biologically active; group; encapsulated; lipid
Prior art date: 1990-03-21

Application number

NO923624A

Other languages

English (en)

Norwegian (no)

Other versions

NO923624D0 (no

NO923624L (no

Inventor

Sinil Kim

Original Assignee

Depotech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-21

Filing date

1992-09-17

Publication date

1999-01-18

1992-09-17 Application filed by Depotech Corp filed Critical Depotech Corp

1992-09-17 Publication of NO923624D0 publication Critical patent/NO923624D0/no

1992-09-17 Publication of NO923624L publication Critical patent/NO923624L/no

1999-01-18 Publication of NO304576B1 publication Critical patent/NO304576B1/no

Links

239000002502 liposome Substances 0.000 title claims abstract description 66
150000002632 lipids Chemical class 0.000 title claims abstract description 39
238000000034 method Methods 0.000 title claims abstract description 36
239000000839 emulsion Substances 0.000 claims abstract description 29
239000000203 mixture Substances 0.000 claims abstract description 22
150000001875 compounds Chemical class 0.000 claims description 65
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
239000007762 w/o emulsion Substances 0.000 claims description 22
239000003960 organic solvent Substances 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
239000002904 solvent Substances 0.000 claims description 15
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
239000008103 glucose Substances 0.000 claims description 13
239000012458 free base Substances 0.000 claims description 10
229960003646 lysine Drugs 0.000 claims description 7
235000012000 cholesterol Nutrition 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
229910001873 dinitrogen Inorganic materials 0.000 claims description 5
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 4
150000003840 hydrochlorides Chemical class 0.000 claims description 4
230000003472 neutralizing effect Effects 0.000 claims description 4
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
108090000623 proteins and genes Proteins 0.000 claims description 4
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 3
230000008020 evaporation Effects 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
150000002430 hydrocarbons Chemical class 0.000 claims description 3
229960005337 lysine hydrochloride Drugs 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
239000003921 oil Substances 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 2
102000055006 Calcitonin Human genes 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
239000011149 active material Substances 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
239000003925 fat Substances 0.000 claims description 2
235000019197 fats Nutrition 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
150000003611 tocopherol derivatives Chemical class 0.000 claims description 2
235000019149 tocopherols Nutrition 0.000 claims description 2
150000003626 triacylglycerols Chemical class 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
239000008158 vegetable oil Substances 0.000 claims description 2
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims 5
238000000889 atomisation Methods 0.000 claims 3
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
239000000159 acid neutralizing agent Substances 0.000 claims 2
238000013019 agitation Methods 0.000 claims 2
150000002170 ethers Chemical class 0.000 claims 2
229960001031 glucose Drugs 0.000 claims 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
-1 sphingomyelin Chemical compound 0.000 claims 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
108010006654 Bleomycin Proteins 0.000 claims 1
108010001857 Cell Surface Receptors Proteins 0.000 claims 1
108010092160 Dactinomycin Proteins 0.000 claims 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
102000003886 Glycoproteins Human genes 0.000 claims 1
108090000288 Glycoproteins Proteins 0.000 claims 1
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
102000000588 Interleukin-2 Human genes 0.000 claims 1
108010002350 Interleukin-2 Proteins 0.000 claims 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
108010000817 Leuprolide Proteins 0.000 claims 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical class C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
229930183665 actinomycin Natural products 0.000 claims 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
150000001413 amino acids Chemical class 0.000 claims 1
229940035676 analgesics Drugs 0.000 claims 1
239000000730 antalgic agent Substances 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
230000001088 anti-asthma Effects 0.000 claims 1
230000001093 anti-cancer Effects 0.000 claims 1
230000003178 anti-diabetic effect Effects 0.000 claims 1
230000000843 anti-fungal effect Effects 0.000 claims 1
230000002959 anti-hypotensive effect Effects 0.000 claims 1
230000002141 anti-parasite Effects 0.000 claims 1
230000000840 anti-viral effect Effects 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
239000000924 antiasthmatic agent Chemical class 0.000 claims 1
239000003472 antidiabetic agent Chemical class 0.000 claims 1
229940121375 antifungal agent Drugs 0.000 claims 1
239000002220 antihypertensive agent Substances 0.000 claims 1
229940124572 antihypotensive agent Drugs 0.000 claims 1
239000003096 antiparasitic agent Chemical class 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
229960001561 bleomycin Drugs 0.000 claims 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
230000000903 blocking effect Effects 0.000 claims 1
229940077731 carbohydrate nutrients Drugs 0.000 claims 1
150000001720 carbohydrates Chemical class 0.000 claims 1
235000014633 carbohydrates Nutrition 0.000 claims 1
229940097217 cardiac glycoside Drugs 0.000 claims 1
239000002368 cardiac glycoside Substances 0.000 claims 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
229960004316 cisplatin Drugs 0.000 claims 1
229960000975 daunorubicin Drugs 0.000 claims 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
229960004679 doxorubicin Drugs 0.000 claims 1
238000004945 emulsification Methods 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
229960000961 floxuridine Drugs 0.000 claims 1
229960002949 fluorouracil Drugs 0.000 claims 1
150000008282 halocarbons Chemical class 0.000 claims 1
230000001024 immunotherapeutic effect Effects 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
239000008101 lactose Substances 0.000 claims 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
229960004338 leuprorelin Drugs 0.000 claims 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
229960001924 melphalan Drugs 0.000 claims 1
102000006240 membrane receptors Human genes 0.000 claims 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
229960001428 mercaptopurine Drugs 0.000 claims 1
229960001156 mitoxantrone Drugs 0.000 claims 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
150000003905 phosphatidylinositols Chemical class 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
239000007921 spray Substances 0.000 claims 1
229930002534 steroid glycoside Natural products 0.000 claims 1
150000008143 steroidal glycosides Chemical class 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
229960001052 streptozocin Drugs 0.000 claims 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
229960001196 thiotepa Drugs 0.000 claims 1
229960003087 tioguanine Drugs 0.000 claims 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
229960005486 vaccine Drugs 0.000 claims 1
229960003048 vinblastine Drugs 0.000 claims 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
229960004528 vincristine Drugs 0.000 claims 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 9
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 9
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 9
229940117972 triolein Drugs 0.000 description 9
239000000725 suspension Substances 0.000 description 6
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 5
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
229940093609 tricaprylin Drugs 0.000 description 4
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 4
238000005538 encapsulation Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
229940067605 phosphatidylethanolamines Drugs 0.000 description 3
150000008106 phosphatidylserines Chemical class 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 2
TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
SKBXVAOMEVOTGJ-UHFFFAOYSA-N xi-Pinol Chemical compound CC1=CCC2C(C)(C)OC1C2 SKBXVAOMEVOTGJ-UHFFFAOYSA-N 0.000 description 2
229960000523 zalcitabine Drugs 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
238000010952 in-situ formation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Saccharide Compounds (AREA)

NO923624A 1990-03-21 1992-09-17 FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom NO304576B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49684690A	1990-03-21	1990-03-21
PCT/US1991/001849 WO1991014445A1 (en)	1990-03-21	1991-03-20	Heterovesicular liposomes

Publications (3)

Publication Number	Publication Date
NO923624D0 NO923624D0 (no)	1992-09-17
NO923624L NO923624L (no)	1992-09-17
NO304576B1 true NO304576B1 (no)	1999-01-18

Family

ID=23974416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923624A NO304576B1 (no)	1990-03-21	1992-09-17	FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom

Country Status (20)

Country	Link
EP (1)	EP0524968B1 (zh)
JP (1)	JP3461000B2 (zh)
KR (1)	KR100203223B1 (zh)
CN (1)	CN1053101C (zh)
AT (1)	ATE123412T1 (zh)
AU (1)	AU655177B2 (zh)
CA (1)	CA2078666C (zh)
DE (1)	DE69110281T2 (zh)
DK (1)	DK0524968T3 (zh)
ES (1)	ES2073164T3 (zh)
FI (1)	FI104464B (zh)
IE (1)	IE62772B1 (zh)
IL (1)	IL97615A (zh)
NO (1)	NO304576B1 (zh)
NZ (1)	NZ237464A (zh)
PT (1)	PT97101B (zh)
RU (1)	RU2120795C1 (zh)
SA (1)	SA93130496B1 (zh)
WO (1)	WO1991014445A1 (zh)
ZA (1)	ZA911974B (zh)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3278273B2 (ja) *	1993-12-17	2002-04-30	キヤノン株式会社	薬剤徐放性カプセル
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
EP1365028B1 (en)	1996-12-13	2009-03-18	Novartis Vaccines and Diagnostics, Inc.	Method for expression of PDGF or IGF proteins in yeast
US5985214A (en)	1997-05-16	1999-11-16	Aurora Biosciences Corporation	Systems and methods for rapidly identifying useful chemicals in liquid samples
IL135060A (en)	1997-09-18	2005-12-18	Skyepharma Inc	Sustained release liposomal anesthetic compositions and methods for the preparation thereof
BR9813930A (pt)	1997-11-06	2006-12-19	Chiron Spa	antìgeno neisserial
AU752802C (en)	1997-11-14	2006-04-13	Pacira Pharmaceuticals, Inc.	Production of multivesicular liposomes
AU1979599A (en)	1998-01-14	1999-08-02	Chiron S.P.A.	(neisseria meningitidis) antigens
CN101293920B (zh)	1998-05-01	2012-07-18	诺华疫苗和诊断公司	脑膜炎奈瑟球菌抗原和组合物
AU1316200A (en)	1998-10-15	2000-05-01	Chiron Corporation	Metastatic breast and colon cancer regulated genes
DE69939599D1 (de)	1998-12-16	2008-10-30	Novartis Vaccines & Diagnostic	MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
US7625859B1 (en)	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US20030008284A1 (en)	2000-06-15	2003-01-09	Giulia Kennedy	Polynucleotides related to colon cancer
BR0010130A (pt)	1999-04-30	2002-06-04	Chiron Spa	Antìgenos de neisseria conservados
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
MXPA02004283A (es)	1999-10-29	2002-10-17	Chiron Spa	Peptidos antigenicos neisseriales.
ES2335386T3 (es)	1999-11-18	2010-03-26	Novartis Vaccines And Diagnostics, Inc.	Gen fgf-21 humano y productos de expresion genica.
BRPI0107679B8 (pt)	2000-01-17	2021-05-25	Chiron Spa	composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
AU2001249125A1 (en)	2000-03-08	2001-09-17	Chiron Corporation	Human fgf-23 gene and gene expression products
EP1950297A2 (en)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
DE60139563D1 (de)	2000-10-27	2009-09-24	Craig J Venter Inst Inc	Nukleinsäuren und proteine von gruppen a und b-streptokokken
WO2002046477A2 (en)	2000-12-07	2002-06-13	Chiron Corporation	Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
WO2002081641A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
US7309783B2 (en)	2001-05-09	2007-12-18	The University Of Connecticut	Mammalian early developmental regulator gene
EP1404713A4 (en)	2001-05-24	2004-09-22	Human Dna Technology Inc	NEW KERATINOCYTE GROWTH FACTOR 2 ANALOG IN HAIR FOLLICULES
DE60236212D1 (de)	2001-11-09	2010-06-10	Univ Georgetown	Neue isoform des gefässendothelzell wachstumshemmers (vegi)
EP2335724A1 (en)	2001-12-12	2011-06-22	Novartis Vaccines and Diagnostics S.r.l.	Immunisation against chlamydia trachomatis
JP4376629B2 (ja)	2002-01-08	2009-12-02	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
JP2005520543A (ja)	2002-03-21	2005-07-14	サイグレスディスカバリー，インコーポレイテッド	癌における新規組成物および方法
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
US8518694B2 (en)	2002-06-13	2013-08-27	Novartis Vaccines And Diagnostics, Inc.	Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US7135324B2 (en)	2002-09-04	2006-11-14	The University Of Connecticut	Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2506318C (en)	2002-11-15	2011-07-12	Chiron Srl	Unexpected surface proteins in neisseria meningitidis
EP1575517B1 (en)	2002-12-24	2012-04-11	Rinat Neuroscience Corp.	Anti-ngf antibodies and methods using same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US20040170982A1 (en)	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
US7767387B2 (en)	2003-06-13	2010-08-03	Sagres Discovery, Inc.	Therapeutic targets in cancer
JP2007524362A (ja)	2003-02-14	2007-08-30	サイグレスディスカバリー，インコーポレイテッド	癌における治療ｇｐｃｒ標的
MXPA05008815A (es)	2003-02-19	2006-05-25	Rinat Neuroscience Corp	Metodos para tratar el dolor al administrar un antagonista del factor de crecimiento de nervios y un farmaco antiinflamatorio no esteroidal y composiciones que contienen los mismos.
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
JP4926707B2 (ja)	2003-08-22	2012-05-09	ダニスコエイ／エス	封入化抗菌材料
GB2388581A (en)	2003-08-22	2003-11-19	Danisco	Coated aqueous beads
BRPI0417270A (pt)	2003-12-23	2007-03-27	Rinat Neuroscience Corp	anticorpos agonistas antitrkc e métodos para utilização dos mesmos
KR20120126130A (ko)	2004-03-29	2012-11-20	가르파마 컴퍼니 리미티드	신규 갈렉틴 9 개변체 단백질 및 그 용도
CA2562024C (en)	2004-04-07	2014-05-27	Rinat Neuroscience Corp.	Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ES2622394T3 (es)	2004-07-09	2017-07-06	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Formas solubles de la glicoproteína g del virus hendra
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
RU2404750C2 (ru)	2004-11-23	2010-11-27	Адамас Фармасьютикалс, Инк.	Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
CA2588296A1 (en)	2004-11-24	2006-06-01	Neuromolecular Pharmaceuticals, Inc.	Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en)	2004-12-13	2011-05-10	University Of Maryland, Baltimore	TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
NZ599345A (en)	2005-02-18	2013-07-26	Novartis Vaccines & Diagnostic	Immunogens from uropathogenic Escherichia Coli
JP5666087B2 (ja)	2005-04-06	2015-02-12	アダマス・ファーマシューティカルズ・インコーポレーテッド	Ｃｎｓ関連疾患の治療のための方法及び組成物
EP1871911A2 (en)	2005-04-07	2008-01-02	Chiron Corporation	Cancer-related genes (prlr)
AU2006235276A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	CACNA1E in cancer diagnosis, detection and treatment
MY148086A (en)	2005-04-29	2013-02-28	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and methods using same
US7462698B2 (en)	2005-07-22	2008-12-09	Y's Therapeutics Co., Ltd.	Anti-CD26 antibodies and methods of use thereof
ES2664854T3 (es)	2005-11-14	2018-04-23	Teva Pharmaceuticals International Gmbh	Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
EP1988920A1 (en)	2006-02-02	2008-11-12	Rinat Neuroscience Corp.	Methods for treating obesity by administering a trkb antagonist
SG172684A1 (en)	2006-06-07	2011-07-28	Bioalliance Cv	Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
US20100015168A1 (en)	2006-06-09	2010-01-21	Novartis Ag	Immunogenic compositions for streptococcus agalactiae
US20100166788A1 (en)	2006-08-16	2010-07-01	Novartis Vaccines And Diagnostics	Immunogens from uropathogenic escherichia coli
EP2134365B1 (en)	2007-03-21	2019-03-13	Effat Emamian	Compositions and methods for inhibiting tumor cell growth
US20100261640A1 (en)	2007-04-10	2010-10-14	Branco Luis M	Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
KR20130087632A (ko)	2007-12-17	2013-08-06	화이자 리미티드	간질성 방광염의 치료
RU2528738C2 (ru)	2007-12-18	2014-09-20	Биоэллаенс К.В.	Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
CA2718975A1 (en)	2008-04-10	2009-10-15	Cell Signaling Technology, Inc.	Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en)	2008-06-13	2009-12-17	Pfizer Inc	Treatment of chronic prostatitis
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Agonist anti-trkb monoclonal antibodies
AU2010220103A1 (en)	2009-03-06	2011-09-22	Novartis Ag	Chlamydia antigens
US20100297127A1 (en)	2009-04-08	2010-11-25	Ghilardi Nico P	Use of il-27 antagonists to treat lupus
MX363222B (es)	2009-04-14	2019-03-15	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
WO2010146511A1 (en)	2009-06-17	2010-12-23	Pfizer Limited	Treatment of overactive bladder
SG177533A1 (en)	2009-07-07	2012-02-28	Novartis Ag	Conserved escherichia coli immunogens
CN102770443A (zh)	2009-07-16	2012-11-07	诺华有限公司	脱毒大肠杆菌免疫原
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
MX365650B (es)	2009-12-02	2019-06-10	Adamas Pharmaceuticals Inc	Composiciones de amantadina y metodos para su uso.
AR080291A1 (es)	2010-02-24	2012-03-28	Rinat Neuroscience Corp	Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
CN105218674A (zh)	2010-03-11	2016-01-06	瑞纳神经科学公司	呈pH依赖性抗原结合的抗体
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) *	2010-05-13	2017-09-26	Pacira Pharmaceuticals, Inc.	Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP2013533286A (ja)	2010-07-30	2013-08-22	セントルイスユニバーシティ	疼痛を治療する方法
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en)	2011-08-22	2013-03-21	Saint Louis University	Compositions and methods for treating inflammation
WO2013028527A1 (en)	2011-08-23	2013-02-28	Indiana University Research And Technology Corporation	Compositions and methods for treating cancer
AR088693A1 (es)	2011-11-11	2014-06-25	Rinat Neuroscience Corp	Anticuerpos especificos para trop-2 y sus usos
WO2013093693A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Staphylococcus aureus specific antibodies and uses thereof
BR112014014824A2 (pt)	2011-12-22	2019-09-24	Rinat Neuroscience Corp	anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
AU2013286866B2 (en)	2012-07-02	2018-03-01	Commonwealth Scientific And Industrial Research Organization	Paramyxovirus and methods of use
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
EP2917237A1 (en)	2012-11-09	2015-09-16	Pfizer Inc.	Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CN111704672B (zh)	2013-03-15	2024-06-04	武田药品工业株式会社	抗血浆激肽释放酶抗体
KR20160005749A (ko)	2013-05-07	2016-01-15	리나트 뉴로사이언스 코프.	항-글루카곤 수용체 항체 및 이의 사용 방법
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
JP6506280B2 (ja)	2013-08-02	2019-05-08	ファイザー・インク	抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
EP3068801A1 (en)	2013-11-13	2016-09-21	Pfizer Inc.	Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
WO2015109212A1 (en)	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
DK3119431T3 (da)	2014-03-21	2024-03-18	Teva Pharmaceuticals Int Gmbh	Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
EP3139955B1 (en)	2014-04-30	2024-03-20	President and Fellows of Harvard College	Fusion proteins for treating cancer and related methods
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en)	2015-04-06	2017-09-12	Yung Shin Pharmaceutical Industrial Co. Ltd.	Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
CN114773476A (zh)	2015-04-13	2022-07-22	辉瑞公司	治疗性抗体和它们的用途
WO2017015334A1 (en)	2015-07-21	2017-01-26	Saint Louis University	Compositions and methods for diagnosing and treating endometriosis-related infertility
JP7068160B2 (ja)	2015-07-21	2022-05-16	武田薬品工業株式会社	第ＸＩＩａ因子のモノクローナル抗体阻害剤
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
MY195443A (en)	2015-08-19	2023-01-21	Pfizer	Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
WO2017049011A1 (en)	2015-09-15	2017-03-23	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
JP6661319B2 (ja) *	2015-09-28	2020-03-11	小林製薬株式会社	リポソーム
TW201722989A (zh)	2015-10-23	2017-07-01	輝瑞大藥廠	抗il-2抗體及其組合物及用途
WO2017075037A1 (en)	2015-10-27	2017-05-04	Scholar Rock, Inc.	Primed growth factors and uses thereof
CN106699889A (zh)	2015-11-18	2017-05-24	礼进生物医药科技（上海）有限公司	抗pd-1抗体及其治疗用途
AU2016381366A1 (en)	2015-12-30	2018-06-28	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of seizure-related disorders
RU2744860C2 (ru)	2015-12-30	2021-03-16	Кодиак Сайенсиз Инк.	Антитела и их конъюгаты
EP3405490B1 (en)	2016-01-21	2021-10-20	Pfizer Inc.	Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
KR102069670B1 (ko) *	2017-03-02	2020-01-23	단디바이오사이언스 주식회사	면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US11198735B2 (en)	2017-03-03	2021-12-14	Rinat Neuroscience Corp.	Anti-GITR antibodies and methods of use thereof
EP3596206A1 (en)	2017-03-16	2020-01-22	Pfizer Inc	Tyrosine prototrophy
CA3059938A1 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
WO2018200885A1 (en)	2017-04-26	2018-11-01	Neurocentria, Inc.	Magnesium compositions and methods of use
CN111247167A (zh)	2017-06-02	2020-06-05	辉瑞公司	Flt3的特异性抗体及其用途
IL270888B1 (en)	2017-06-13	2024-08-01	Bostongene Corp	Systems and methods for identifying cancer treatments from normalized Biosman scores
KR20200028982A (ko)	2017-07-13	2020-03-17	메사추세츠 인스티튜트 오브 테크놀로지	시냅스 기능을 증진시키기 위한 hdac2-sp3 복합체 표적화
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
EP3692370A2 (en)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Articles and methods directed to personalized therapy of cancer
KR20200115596A (ko)	2018-02-01	2020-10-07	화이자 인코포레이티드	Cd70에 특이적인 항체 및 이의 용도
EP3746483A1 (en)	2018-02-01	2020-12-09	Pfizer Inc	Chimeric antigen receptors targeting cd70
TWI776024B (zh)	2018-02-28	2022-09-01	美商輝瑞大藥廠	Il-15變體及其用途
SG11202010934SA (en)	2018-05-23	2020-12-30	Pfizer	Antibodies specific for gucy2c and uses thereof
KR102602329B1 (ko)	2018-05-23	2023-11-16	화이자 인코포레이티드	Cd3에 특이적인 항체 및 이의 용도
EP3994696A2 (en)	2019-07-03	2022-05-11	BostonGene Corporation	Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
AU2020363372A1 (en)	2019-10-07	2022-05-19	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
AU2020364071A1 (en)	2019-10-10	2022-05-26	Kodiak Sciences Inc.	Methods of treating an eye disorder
CA3152623A1 (en)	2019-10-11	2021-04-15	Richard D. Cummings	Anti-tn antibodies and uses thereof
WO2021151079A1 (en)	2020-01-24	2021-07-29	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en)	2020-04-08	2021-10-14	Pfizer Inc.	Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en)	2020-05-06	2021-11-11	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
CA3189590A1 (en)	2020-07-17	2022-01-20	Pfizer Inc.	Therapeutic antibodies and their uses
US20230287455A1 (en)	2020-07-30	2023-09-14	Pfizer Inc.	Cells Having Gene Duplications and Uses Thereof
JP2023540098A (ja)	2020-09-03	2023-09-21	チェンアーヴィンエス．ワイ．	可溶性アルカリホスファターゼ構築物及び可溶性アルカリホスファターゼ構築物をコードするポリヌクレオチドを含む発現ベクター
WO2022120256A2 (en)	2020-12-04	2022-06-09	Bostongene Corporation	Hierarchical machine learning techniques for identifying molecular categories from expression data
US11033495B1 (en)	2021-01-22	2021-06-15	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en)	2021-01-22	2022-03-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en)	2021-01-22	2022-06-14	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
JP2024517745A (ja)	2021-04-29	2024-04-23	ボストンジーンコーポレイション	複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
EP4380969A1 (en)	2021-08-02	2024-06-12	Pfizer Inc.	Improved expression vectors and uses thereof
AU2023213817A1 (en)	2022-01-31	2024-08-01	Bostongene Corporation	Machine learning techniques for cytometry
WO2023148598A1 (en)	2022-02-02	2023-08-10	Pfizer Inc.	Cysteine prototrophy
WO2024015561A1 (en)	2022-07-15	2024-01-18	Bostongene Corporation	Techniques for detecting homologous recombination deficiency (hrd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2408387A2 (fr) *	1975-06-30	1979-06-08	Oreal	Compositions a base de dispersions aqueuses de spherules lipidiques
CH624011A5 (zh) *	1977-08-05	1981-07-15	Battelle Memorial Institute
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) *	1983-08-01	1988-06-07	Michael W. Fountain	Enhancement of pharmaceutical activity
EP0199362A3 (en) *	1985-04-26	1987-10-07	Massachusetts Institute Of Technology	System and apparatus for delayed and pulsed release of biologically active substances
FR2591105B1 (fr) *	1985-12-11	1989-03-24	Moet Hennessy Rech	Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) *	1987-02-23	1987-04-01	Clayton Found Res	Multivesicular liposomes

1991
- 1991-03-18 ZA ZA911974A patent/ZA911974B/xx unknown
- 1991-03-18 NZ NZ237464A patent/NZ237464A/en unknown
- 1991-03-19 IE IE91191A patent/IE62772B1/en not_active IP Right Cessation
- 1991-03-20 DK DK91906733.0T patent/DK0524968T3/da active
- 1991-03-20 WO PCT/US1991/001849 patent/WO1991014445A1/en active IP Right Grant
- 1991-03-20 AT AT91906733T patent/ATE123412T1/de not_active IP Right Cessation
- 1991-03-20 AU AU75806/91A patent/AU655177B2/en not_active Ceased
- 1991-03-20 DE DE69110281T patent/DE69110281T2/de not_active Expired - Lifetime
- 1991-03-20 ES ES91906733T patent/ES2073164T3/es not_active Expired - Lifetime
- 1991-03-20 EP EP91906733A patent/EP0524968B1/en not_active Expired - Lifetime
- 1991-03-20 IL IL9761591A patent/IL97615A/en not_active IP Right Cessation
- 1991-03-20 JP JP50728091A patent/JP3461000B2/ja not_active Expired - Lifetime
- 1991-03-20 CA CA002078666A patent/CA2078666C/en not_active Expired - Lifetime
- 1991-03-21 RU SU5053129A patent/RU2120795C1/ru not_active IP Right Cessation
- 1991-03-21 PT PT97101A patent/PT97101B/pt not_active IP Right Cessation
- 1991-03-21 CN CN91102478A patent/CN1053101C/zh not_active Expired - Fee Related
1992
- 1992-09-17 NO NO923624A patent/NO304576B1/no unknown
- 1992-09-18 FI FI924193A patent/FI104464B/fi active
- 1992-09-21 KR KR1019920702302A patent/KR100203223B1/ko not_active IP Right Cessation
1993
- 1993-04-27 SA SA93130496A patent/SA93130496B1/ar unknown

Also Published As

Publication number	Publication date
ATE123412T1 (de)	1995-06-15
EP0524968B1 (en)	1995-06-07
ES2073164T3 (es)	1995-08-01
CA2078666A1 (en)	1991-09-22
DE69110281T2 (de)	1995-11-09
IE62772B1 (en)	1995-02-22
IL97615A0 (en)	1992-06-21
NZ237464A (en)	1995-02-24
JPH05507680A (ja)	1993-11-04
FI104464B (fi)	2000-02-15
IL97615A (en)	1995-06-29
PT97101B (pt)	1998-08-31
SA93130496B1 (ar)	2004-08-14
RU2120795C1 (ru)	1998-10-27
CN1055663A (zh)	1991-10-30
EP0524968A1 (en)	1993-02-03
IE910911A1 (en)	1991-09-25
KR100203223B1 (ko)	1999-06-15
NO923624D0 (no)	1992-09-17
FI924193A (fi)	1992-09-18
CA2078666C (en)	2001-10-02
AU655177B2 (en)	1994-12-08
NO923624L (no)	1992-09-17
JP3461000B2 (ja)	2003-10-27
AU7580691A (en)	1991-10-21
FI924193A0 (fi)	1992-09-18
ZA911974B (en)	1994-08-22
PT97101A (pt)	1991-11-29
DE69110281D1 (de)	1995-07-13
EP0524968A4 (en)	1993-03-24
DK0524968T3 (da)	1995-07-31
CN1053101C (zh)	2000-06-07
WO1991014445A1 (en)	1991-10-03

Publication	Publication Date	Title
NO304576B1 (no)	1999-01-18	FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom
EP0280503B9 (en)	2004-04-21	Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US6106858A (en)	2000-08-22	Modulation of drug loading in multivescular liposomes
JP3002702B2 (ja)	2000-01-24	活性物質の制御放出を有する小胞
FI119621B (fi)	2009-01-30	Multivesikulääristen liposomien valmistus aktiivisten aineiden vapauttamiseksi kontrolloidusti
KR930700134A (ko)	1993-03-13	이종 소포 리포좀
JP2008163040A (ja)	2008-07-17	封入された化合物のパーセントが増加したリポソーム
US5576017A (en)	1996-11-19	Heterovesicular liposomes
US5173219A (en)	1992-12-22	Uniform spherical multilamellar liposomes of defined and adjustable size distribution
KOSHIZAKA et al.	1989	Novel liposomes for efficient transfection of β-galactosidase gene into COS-1 cells
NZ247547A (en)	1996-01-26	Process for preparing heterovesicular lipid vesicles or liposomes; vesicles containing a chloride and an active agent